Status:
COMPLETED
Optimal Effect-site Concentration of Remifentanil for Inhibiting Response to Laryngeal Mask Airway (LMA) Removal
Lead Sponsor:
Sangjin Park
Conditions:
Respiratory Complication
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
This study was designed to determine the optimal dose of remifentanil that can prevent the complications associated with the removal of LMA without delaying emergence.
Detailed Description
Patients were randomly assigned to one of four groups. All patients received a predetermined effect-site concentrations (Ce) of remifentanil by target-controlled infusion (TCI) according to their grou...
Eligibility Criteria
Inclusion
- American Society of Anesthesiologists physical status 1 or 2
- undergoing lower extremity surgery under general anesthesia
Exclusion
- suspected difficult airways
- respiratory disease (chronic obstructive pulmonary disease, upper respiratory infection)
- body mass index \> 30 kg/m2
- allergies to the study drugs
- a history of gastric reflux
Key Trial Info
Start Date :
July 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2013
Estimated Enrollment :
128 Patients enrolled
Trial Details
Trial ID
NCT01915108
Start Date
July 1 2012
End Date
June 1 2013
Last Update
August 25 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.